Doha: The Qatari Red Crescent Society (QRCS) signed Wednesday a Memorandum of Understanding (MoU) with AbbVie, the world’s leading biopharmaceutical company, to implement a charity program called “Salamtak,” designed to support patients with autoimmune disorders who are unable to afford treatment.
This support will be based on HMC medical reports and case studies prepared by the cadres of social workers in the Qatar Red Crescent. The agreement was signed by Executive Director of QRCS Volunteering and Local Development Noura Rashed Al Dosari, Executive Director of the Qatar Red Crescent Volunteer and Local Development Sector, and by AbbVie’s General Manager for the South Gulf Region Sami Abi Nakhoul.
She pointed out that extending a helping hand to these patients and restoring hope to them in healing is a noble work that requires the solidarity of all to achieve the desired results. She also highlighted the importance of the strategic partnership between QRCS and Hamad Medical Corporation (HMC). Al Dosari also praised Abbvie, which cooperated with QRCS before in a campaign for protecting liver. It involved providing free health attention to residents who suffered from Hepatitis, the campaign achieved a 100 percent cure rate.
For his part, Abi Nakhoul said that Abbvie was committed to supporting the efforts of HMC and QRCS in improving healthcare in the country, which will ultimately benefit the patients. He also stressed that the continued partnership between the three sides will be crucial to the success of Salamtak.
Source: The Peninsula Newspaper